PD-(L)1 Inhibitors as Single-Agent or in Combination with Chemotherapy for Advanced, PD-L1-high Non-Small Cell Lung Cancer: A Meta-Analysis
Alessandro Di Federico, Andrea De Giglio, Giacomo Nuvola, Chiara Deiana, Nicole Conci, Francesco Gelsomino, Andrea Ardizzoni
Abstract
The combination of a PD-(L)1 inhibitor and CT appears to be associated with improved PFS and ORR, but similar OS, compared with PD-(L)1 inhibitor single-agent therapy in patients with PD-L1-high non-small-cell lung cancer.
Topics & Concepts
MedicineInternal medicineLung cancerOncologyChemotherapyAdverse effectMeta-analysisRandomized controlled trialCombination therapyGastroenterologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies